Content area

|
|

Forebyggelse af reaktivering af hepatitis B og hepatitis C ved immunsupprimerende behandling

Forfatter(e)
Malene Risum1 & Toke Seierøe Barfod2
1) Hæmatologisk Afdeling, Rigshospitalet 2) Medicinsk Afdeling, Sjællands Universitetshospital, Roskilde

Ugeskr Læger 2019;181:V08180568
Reference: 
Ugeskr Læger 2019;181:V08180568

Malene Risum & Toke Seierøe Barfod:

Prophylaxis of reactivation of hepatitis B and hepatitis C virus infection in immunosuppressive therapy

Ugeskr Læger 2019;181:V08180568

The use of immunosuppressive agents can be vital. However, immunosuppression may also cause reactivation of hepatitis B virus (HBV) infection which can be fatal. To reduce the risk of reactivation prophylactic antiviral treatment is recommended in patients with chronic HBV infection. In patients with former HBV infection prophylaxis is also recommended if anti-CD20 agents are used and in cases of transplantation. Immunosuppression in patients with hepatitis C virus (HCV) infection does not seem to lead to severe hepatic manifestations, and reactivation of HCV in this context generally has a mild clinical course.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Morten Holm | 24/03
17 kommentarer
af Astrid Hanna M. Schulze | 23/03
1 Kommentar
af Christian Schlütter | 23/03
10 kommentarer
af Poul Erik Rørbæk | 22/03
29 kommentarer
af Niels Foldager | 19/03
1 Kommentar
af Stig Gerdes | 18/03
4 kommentarer
af Gorm Greisen | 17/03
1 Kommentar
af Lars Erik Larsen | 17/03
5 kommentarer